Modulatory Effect of the Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen on Circulating Immune Cells in Systemic Lupus Erythematosus
Jazyk angličtina Země Polsko Médium print-electronic
Typ dokumentu časopisecké články
Grantová podpora
FNOL
Ministerstvo Zdravotnictví České Republiky
00098892
Ministerstvo Zdravotnictví České Republiky
IGA_LF_2019_006
Univerzita Palackého v Olomouci
IGA_LF_2019_014
Univerzita Palackého v Olomouci
PubMed
31620814
DOI
10.1007/s00005-019-00563-4
PII: 10.1007/s00005-019-00563-4
Knihovny.cz E-zdroje
- Klíčová slova
- Cyclophosphamide, Flow cytometry, Immunophenotyping, Lupus nephritis, SLE, Treatment outcome,
- MeSH
- cyklofosfamid terapeutické užití MeSH
- dospělí MeSH
- imunologická paměť MeSH
- imunomodulace MeSH
- imunosupresiva terapeutické užití MeSH
- indukce remise MeSH
- intravenózní podání MeSH
- klinické protokoly MeSH
- kohortové studie MeSH
- krevní oběh MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfocyty účinky léků imunologie MeSH
- mladý dospělý MeSH
- nefritida při lupus erythematodes farmakoterapie MeSH
- průtoková cytometrie MeSH
- systémový lupus erythematodes farmakoterapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- cyklofosfamid MeSH
- imunosupresiva MeSH
A Euro-Lupus regimen of low-dose intravenous cyclophosphamide (CFA) is commonly used to treat severe organ manifestations of systemic lupus erythematosus (SLE), particularly lupus nephritis (LN). There are no data on the distributions and dynamics of immune cell populations in patients with various treatment outcomes. The circulating immune cells of 11 female SLE patients were assessed before and after Euro-Lupus regimen (cumulative dose of 3000 mg CFA) by flow cytometry together with those of 16 healthy women. A subanalysis was performed in LN patients who achieved complete remission (CR; n = 3), partial remission (PR; n = 4), and no response (NR; n = 2). In SLE, the Euro-Lupus regimen decreased the percentage and absolute count of B cells; increased the percentage of CD8+ T cells, T regulatory cells, neutrophils, and monocyte subsets; and activated T and NK cells compared to healthy controls (P < 0.050). Patients with LN achieving CR had significantly lower proportions of CD27+ B memory cells compared to poor responders (PR/NR, P = 0.035). The post-treatment percentages and absolute numbers of B cells, T cells, NK cells, monocytes, and neutrophils showed high inter-individual variability with no association with treatment outcome. Our pilot study revealed the dynamics of changes in immune cell populations in SLE patients during a Euro-Lupus regimen, mainly the lowering of B cells. In LN patients who achieved CR, a lower proportion of CD27+ B memory cells was evident compared to poor responders (PR/NR). Further studies on usefulness of monitoring immune cells for treatment response prediction on larger cohorts are needed.
Citace poskytuje Crossref.org
